Key facts
- Artios’s last known valuation is $260.3M (Nov 2025).
- It has raised $384.5M across 1 recorded rounds; the latest was Later Stage VC (Series D) ($114.4M) in Nov 2025.
- Notable investors include RA Capital Management, Sofinnova Partners, M Ventures, The Invus Group, SV Health Investors — 27 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Artios
Funding rounds
1 roundsAbout Artios
Developer of novel cancer treatments designed to target the deoxyribonucleic acid (DNA) damage response. The company's treatments focus on developing therapies through deoxyribonucleic acid damage response pathways to help mutations in their DNA so that they can evolve, enabling physicians to selectively kill cancer cells through a concept known as synthetic lethality.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2015
- Employees
- 121
- Website
- artios.com/
- Ownership
- Privately Held (backing)
Artios doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Artios shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Artios in its N-PORT filings yet. We sweep new filings monthly.